Earnings
The transaction, expected to close in the third quarter of this year, includes TeneoTwo’s proposed drug for relapsed and refractory B-cell non-Hodgkin lymphoma TNB-486.
Rather than selling, Novartis could spin Sandoz off into its own separate entity with its own listing on a stock exchange.
In addition to patent cases, partnerships and pledging money to global tropical disease efforts, Novartis scored a win on a combo-treatment for solid tumors.
DEM BioPharma has $70 million to get started on novel immunotherapeutics to treat cancer following a successful financing round.
Galapagos announced that it had acquired CellPoint and AboundBio in an all-cash transaction, greatly expanding its drug portfolio.
Therorna brought in $42 million to advance its circular RNA platform, while Carbon Biosciences banked $38 million to develop therapies for genetic diseases, beginning with cystic fibrosis.
Pharmaceutical giant Merck is exploring a possible purchase of biotech company Seagen, according to The Wall Street Journal.
According to reports citing “people familiar with the matter,” Kyowa Kirin, a specialty pharma company, could be lining up the sale of $1 billion worth of assets on the international market.
The Forbion Growth Opportunities Fund II will invest mainly in later-stage biopharmaceutical firms in Europe, focusing on marketing treatments for diseases with high unmet needs.
With June just getting started, BMS and Sorrento are making new connections. Read on for announcements of these collaborations.
PRESS RELEASES